The intended audience for this educational initiative is primary care providers, including internal medicine and family medicine physicians, nurse practitioners, and physician assistants, who are front-line clinicians in managing patients with type 2 diabetes.
Upon completion of this activity, participants should be able to:
Describe the pleiotropic mechanism of action of GLP-1 receptor agonists.
Discuss efficacy and safety data for approved GLP-1 receptor agonists, including efficacy for glycemic and extra-glycemic effects.
Incorporate GLP-1 receptor agonists into evidence-based individualized management plans for patients with type 2 diabetes aligned with current guideline recommendations.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.
Faculty, Authors, and Content Developers
The faculty, authors and content developers reported the following relevant financial relationships with ineligible companies:
Lucia M. Novak, MSN, ANP-BC, BC-ADM
Board Certified Adult Health and Advanced Diabetes Management
President and Owner
Diabetes Consulting Services
North Bethesda, Maryland
Capital Health & Metabolic Center
Capital Diabetes & Endocrine Associates
Camp Springs and Silver Spring, Maryland
Lucia M. Novak, MSN, ANP-BC, BC-ADM: Consulting Fee: Abbott Diabetes Care, Novo Nordisk, Provention Bio, Xeris; Speaker's Bureau: Abbott Diabetes Care, BI/Lilly, Novo Nordisk, Xeris.
Jay H. Shubrook, DO, FACOFP, FAAFP
Department of Clinical Sciences and Community Health
Touro University California
College of Osteopathic Medicine
Jay H. Shubrook, DO, FACOFP, FAAFP: Consulting Fee: Abbott, Astra Zeneca, Bayer, Eli Lilly, Nevro, Novo Nordisk
John White, Jr., PA-C, PharmD
Chair and R. Keith Campbell Distinguished Professor in Diabetes Care
Department of Pharmacotherapy
Washington State University College of Pharmacy and Pharmaceutical Sciences
John R. White, Jr., PA-C, PharmD: Consulting Fee: Novo Nordisk; Stock Shareholder: Emishere Technologies
Eugene Wright, MD
Medical Director, Performance Improvement
Eugene Wright, MD: Consulting Fee: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Medtronic, Sanofi; Honoraria: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Medtronic, Sanofi; Speakers' Bureau: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Lilly, Sanofi
Brian W. Jack, MD: has no relevant financial relationships.
Planners and Managers
The planners and managers reported the following relevant financial relationships with ineligible companies:
Terry A. Glauser, MD, MPH: has no relevant financial relationships
The content reviewers reported the following financial relationships with ineligible companies:
Katie Propst, PhD: has no relevant financial relationships
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement
The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email firstname.lastname@example.org
ABIM MOC Designation Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To recieve CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME's ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
AAFP Credit Designation Statement
The AAFP has reviewed GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM- Enduring and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 08/30/2022 to 08/30/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Association of Nurse Practitioners (AANP) Credit Designation Statement
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22065626. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Assistants (AAPA) Credit Designation Statement
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 8/30/2022 to 8/30/2023. AAPA reference number: CME-207846.
ABMS MOC Approval Statement
Through the American Board of Medical Specialties ("ABMS") ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, GLP-1 Receptor Agonists: Metabolic Effects and Their Role in Managing T2DM has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
ABMS Lifelong Learning CME Activity